HanAll Biopharma Co Ltd (009420):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:HanAll Biopharma Co Ltd (009420) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3489
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
HanAll Biopharma Co Ltd (HanAll), formerly HanAll Pharmaceutical Co Ltd, is a pharmaceutical company that offers drug delivery, biotherapeutics, and small molecule discovery programs. The company develops drugs in therapeutic areas of ophthalmology, immunology, cardiovascular disease, dermatology and biobetter. It offers drug research and development, medical information and advanced products. HanAll operates through its research and development center and biotechnology research institute. The company’s products are used in treatment of autoimmune diseases, dry eye diseases, and recurrent and intractable cancer. It has operations in South Korea and the US. HanAll is headquartered in Seoul, South Korea.

HanAll Biopharma Co Ltd (009420) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
HanAll Biopharma Enters into Licensing Agreement for OmniAb Antibody 11
Roivant Sciences Enters into Licensing Agreement with HanAll Biopharma 12
Harbour BioMed Enters into Licensing Agreement with HanAll Biopharma 13
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 14
Equity Offering 15
Hanall Biopharma to Raise USD0.3 Million in Public Offering of Shares 15
Acquisition 16
Yuhan Completes Acquisition Of 9.1% Stake In Hanall For US$27 Million 16
HanAll Biopharma Co Ltd – Key Competitors 17
HanAll Biopharma Co Ltd – Key Employees 18
HanAll Biopharma Co Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
HanAll Biopharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
HanAll Biopharma Enters into Licensing Agreement for OmniAb Antibody 11
Roivant Sciences Enters into Licensing Agreement with HanAll Biopharma 12
Harbour BioMed Enters into Licensing Agreement with HanAll Biopharma 13
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 14
Hanall Biopharma to Raise USD0.3 Million in Public Offering of Shares 15
Yuhan Completes Acquisition Of 9.1% Stake In Hanall For US$27 Million 16
HanAll Biopharma Co Ltd, Key Competitors 17
HanAll Biopharma Co Ltd, Key Employees 18
HanAll Biopharma Co Ltd, Other Locations 19

List of Figures
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[HanAll Biopharma Co Ltd (009420):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Medusa Mining Ltd:企業の戦略・SWOT・財務情報
    Medusa Mining Ltd - Strategy, SWOT and Corporate Finance Report Summary Medusa Mining Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Anadolu Anonim Turk Sigorta Sirketi:企業の戦略・SWOT・財務情報
    Anadolu Anonim Turk Sigorta Sirketi - Strategy, SWOT and Corporate Finance Report Summary Anadolu Anonim Turk Sigorta Sirketi - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Meidensha Corporation:企業の戦略・SWOT・財務情報
    Meidensha Corporation - Strategy, SWOT and Corporate Finance Report Summary Meidensha Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • H. Lundbeck AS (LUN):企業の財務・戦略的SWOT分析
    H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • BSN medical GmbH:企業の戦略的SWOT分析
    BSN medical GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • The Empire District Electric Company:企業の戦略的SWOT分析
    The Empire District Electric Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Reliance Industries Limited:企業の戦略・SWOT・財務分析
    Reliance Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Reliance Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Ascena Retail Group, Inc. (ASNA):企業の財務・戦略的SWOT分析
    Ascena Retail Group, Inc. (ASNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Magnotta Winery Corporation:企業の戦略・SWOT・財務情報
    Magnotta Winery Corporation - Strategy, SWOT and Corporate Finance Report Summary Magnotta Winery Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Xcel Energy Inc (XEL)-エネルギー分野:企業M&A・提携分析
    Summary Xcel Energy Inc. (Xcel Energy) is a vertically-integrated energy utility that generates, procures, transmits, distributes and sells electricity; and transports, stores and distributes natural gas through its subsidiaries. The company owns and operates generation assets utilizing diverse fuel …
  • Alamo Group, Inc.:企業の戦略・SWOT・財務情報
    Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Micell Technologies Inc:製品パイプライン分析
    Summary Micell Technologies Inc (Micell) is a medical device company that develops drug delivery systems for the treatment of cardiovascular diseases. The company offers product such as MiStent sirolimus eluting absorbable polymer coronary stent system, a drug-eluting stent that is designed to optim …
  • Alstom SA (ALO)-エネルギー分野:企業M&A・提携分析
    Summary Alstom SA (Alstom) is a manufacturer of transportation vehicles. It designs, develops and manufactures rail transport equipment, systems, services and signaling for urban, suburban, regional and main line passenger transportation, and for freight transportation. The company offers a wide ran …
  • Trevena Inc (TRVN):企業の財務・戦略的SWOT分析
    Summary Trevena Inc (Trevena) is a biotechnology company that discovers and develops G-protein coupled receptor targeted medicines. The company provides products such as RV027, TRV130, TRV734 and TRV250. Its TRV027 is an intravenous drug used for the treatment of acute heart failure in combination w …
  • RainDance Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary RainDance Technologies Inc (RDT), a subsidiary of Bio-Rad Laboratories Inc is a developer of genomic tools for non-invasive liquid biopsy applications. The company’s products include RainDrop Plus, a digital PCR system that provides picoliter droplets for multiplex detection of HIV and DNA; …
  • Gedeon Richter Plc:企業の戦略・SWOT・財務情報
    Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report Summary Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Discovery Communications, Inc.
    Discovery Communications, Inc. - Strategy, SWOT and Corporate Finance Report Summary Discovery Communications, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Larsen & Toubro Infotech Ltd (LTI):企業の財務・戦略的SWOT分析
    Larsen & Toubro Infotech Ltd (LTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Mitsui & Co., Ltd.:企業の戦略・SWOT・財務情報
    Mitsui & Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsui & Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Phillips-Medisize Corp:医療機器:M&Aディール及び事業提携情報
    Summary Phillips-Medisize Corp (Phillips-Medisize) is a provider of outsourced design and manufacturing services to medical, defense, consumer, and automotive markets. The company operates as a subsidiary of Molex LLC. It offers a broad range of pre-production and production services. The company of …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆